CNCE News 9.35 04/25/2014 05:16:10 Concert Pharmaceuticals Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Concert Pharmaceuticals Inc. (CNCE) 9.35 $CNCE

Concert Pharmaceuticals, Inc. [CNCE] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 11, 9:00AM CDT
What:

Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014

Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.

Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.

Concert Pharmaceuticals Reports Year End 2013 Financial Results
Business Wire - Mon Mar 31, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting
Business Wire - Wed Mar 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT. A corresponding poster presentation will also be presented at the meeting and will include data describing the effect of CTP-499 treatment on several biomarkers of fibrosis. A copy of the corresponding abstract is available on the National Kidney Foundation's website at: http://www.kidney.org/news/meetings/clinical/.../index.cfm.

Concert Pharmaceuticals elects Dr Wendell Wierenga to board
M2 - Mon Mar 17, 5:05AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) revealed on Friday the addition of Dr Wendell Wierenga, PhD to its board of directors.

Company Profile for Concert Pharmaceuticals, Inc.
Business Wire - Fri Mar 14, 9:40AM CDT
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors
Business Wire - Fri Mar 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today the appointment of Wendell Wierenga, Ph.D. to its board of directors. Dr. Wierenga is a seasoned executive with broad experience across all aspects of research, drug discovery and drug development including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. Over the course of his career, he has been involved in over 70 INDs, 15 NDAs and 16 marketed products, including Lipitor(R), Neurontin(R), and Uceris(R).

Concert Pharmaceuticals Announces Exercise of Over-Allotment Option
Business Wire - Mon Mar 03, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 649,690 shares. The additional shares were sold at the public offering price of $14.00 per share, before underwriting discounts. The closing occurred on March 3, 2014, bringing the total number of shares sold by Concert in the initial public offering to 6,649,690 shares, which represents a total capital raise of approximately $93 million before underwriting discounts.

Concert Pharmaceuticals to Present at the 26th Annual ROTH Conference on March 10, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will present a corporate overview at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:00 a.m. PDT at the Ritz-Carlton Laguna Niguel, CA.

Concert Pharmaceuticals concludes IPO of 6m common shares
M2 - Thu Feb 20, 5:20AM CST
US-based biopharmaceutical company Concert Pharmaceuticals Inc (NasdaqGM:CNCE) revealed on Wednesday the completion of its initial public offering of 6m shares of its common stock.

Concert Pharmaceuticals Announces Closing of Initial Public Offering
Business Wire - Wed Feb 19, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts.

Concert Pharmaceuticals Announces Pricing of Initial Public Offering
Business Wire - Thu Feb 13, 7:00AM CST
Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Business Wire - Thu Jan 23, 6:00AM CST
Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 9

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 89

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 119

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 156

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 132

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

Social Media Buzz Powers Hainan's Travel Boom

Updated Category News Views 205

Social Media Buzz Powers Hainan's Travel Boom This year marks a remarkable shift in Hainan's tourism, driven by the advent of visa-free travel access for international visitors. As the beautiful island in southern China opens its doors wider, a surge in travelers, especially travel bloggers from around the globe, is noticeable. Influencers from diverse backgrounds,...

Continue Reading
Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates

Updated Category News Views 375

Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates Kodiak Sciences Inc. (Nasdaq: KOD) has recently shared significant business highlights along with financial results for the third quarter of 2025. This biotechnology company is making strides in the field of retinal medicine. 'We are witnessing a period marked by sustained momentum,' expressed Victor...

Continue Reading
Vaisala Initiates Share Repurchase Program to Enhance Incentives

Updated Category News Views 193

Vaisala’s Strategy for Share Repurchases Vaisala Corporation is embarking on an important journey to repurchase its own shares as part of a broader incentive plan. This strategic decision follows the authorization granted by the Annual General Meeting, reflecting the company's commitment to fostering a rewarding environment for its employees. As a key player in climate...

Continue Reading
Investigating Customer Bancorp, Inc. Losses: Understand Your Rights

Updated Category News Views 92

Exploring Customers Bancorp, Inc.'s Recent Challenges Customers Bancorp, Inc., identified by the ticker CUBI, is dealing with significant accusations regarding the truthfulness of the business information it has shared with the public. The Rosen Law Firm, a respected advocate for investor rights, is currently looking into securities claims tied to these allegations. If...

Continue Reading
Allurity and Onevinn: Transforming Cybersecurity Together

Updated Category News Views 374

Allurity Expands its Cybersecurity Portfolio with Onevinn Acquisition Allurity, a prominent European provider of cybersecurity services, has exciting news to share. The company has taken a significant step forward by acquiring Onevinn, a Swedish company renowned for its intelligent security and managed services. This move not only showcases Allurity's ambitions but also...

Continue Reading